Skip to main content


  • Caption

Urenco increases its stable isotopes offering

07 April 2021

Urenco is taking a considerable step forward in the production of stable isotopes in 2021.

The growing market in this field has led us to expand our facility to meet the demand, especially for products in the medical and the semiconductor field.

One of the products, Xenon 129, will be used in MRI imaging to detect lung diseases. We are also doing research to support solutions for cancer treatment. Already, hundreds of thousands of patients are treated every year with products made from our enriched stable isotopes. Other applications of our products are very varied and include super-fast computer processing power development and experimental research programmes which search for the ultra-rare neutrino-less double-beta decay.

This demonstrates the versatility of our centrifuge technology, which is not limited to the separation of uranium isotopes. It can also be used for the separation of other isotopes – including cadmium, germanium, iridium, molybdenum, selenium, tellurium, titanium, tungsten, xenon and zinc – for medical, industrial and research applications.

We have gained expertise in this area for over three decades at our enrichment facility in the Netherlands, supporting the improvement of medical diagnostics, therapy, and many other fields, and building a substantial portfolio of enriched and depleted products for a wide range of markets and customers.

Martijn van Hezel, Commercial Manager Stable Isotopes, said: “We are looking forward to working with customers on new research and development projects, producing high-quality, cost-efficient products and solutions that will change lives and thrive prosperity.”


About Urenco

Urenco is an international supplier of enrichment services and fuel cycle products with sustainability at the core of its business. Operating in a pivotal area of the nuclear fuel supply chain for 50 years, Urenco facilitates zero carbon electricity generation for consumers around the world.

With its head office near London, UK, Urenco’s global presence ensures diversity and security of supply for customers through enrichment facilities in Germany, the Netherlands, the UK and the USA. Using centrifuge technology designed and developed by Urenco, and through the expertise of our people, the Urenco Group provides safe, cost effective and reliable services; operating within a framework of high environmental, social and governance standards, complementing international safeguards.

Urenco is committed to continued investment in the responsible management of nuclear materials; innovation activities with clear sustainability benefits, such as nuclear medicine, industrial efficiency and research; and nurturing the next generation of scientists and engineers.


Sign up to our newsletter by entering your email address below.

Back to
the goals